The company said it had entered into an agreement with the National Institute of Allergy and Infectious Diseases to study the baricitinib drug to examine its efficacy and safety as a potential treatment for hospitalized patients diagnosed with COVID-19. Lilly had previously been testing the Olumiant or baricitinib drug as a treatment for atopic dermatitis. Lilly said it currently does not anticipate shortages for any of its medicines, including baricitinib. …read more
Source:: Yahoo Finance
